Publication: FiercePharma

First reported Apr 18 2014 - Updated Apr 18 2014 - 1 reports

Eventus attracts $2.72M for breast cancer Dx testing and commercial expansion

Eventus Diagnostics in Miami raised a $2.72 million investment infusion that it will use to advance its Octava breast cancer diagnostic blood tests. They are designed for use along with annual mammograms to spot cancer or determine its absence by measuring ... [Published FiercePharma - Apr 18 2014]
First reported Apr 17 2014 - Updated Apr 18 2014 - 1 reports

GlaxoSmithKline steps up bribery probes, eyeing potential violations in 9 Middle Eastern countries

GlaxoSmithKline ($GSK) has added two more countries to its bribery-investigation list. The U.K.-based drugmaker now says it faces probes in Jordan and Lebanon, in addition to recently announced investigations in Iraq and Poland.Together with the behemoth ... [Published FiercePharma - Apr 17 2014]
First reported Apr 17 2014 - Updated Apr 17 2014 - 1 reports

Novartis near to wrapping up $1.7B sale of part-owned patchmaker LTS Lohmann

It's been almost a yearlong contest, but a deal for patchmaker LTS Lohmann appears to be nearing the finish line. The private equity firm Nordic Capital is likely to beat out competitor Wendel for the deal, Bloomberg says, at a price of about $1.7 bi ... [Published FiercePharma - Apr 17 2014]
First reported Apr 17 2014 - Updated Apr 17 2014 - 1 reports

Gardasil dose reduction could boost EU sales for Merck-Sanofi joint venture

Now that the European Commission has officially approved a two-dose Gardasil regimen for early teens, Merck ( $MRK ) and Sanofi ( $SNY )--who market the HPV vaccine in Europe through joint venture Sanofi Pasteur MSD--will see the number of shots per patient ... [Published FiercePharma - Apr 17 2014]
First reported Apr 17 2014 - Updated Apr 17 2014 - 1 reports

Under fire from local pharmas, China backs off price caps

China is on track to become the world's second-largest drug market by 2020, provided its policy of capping retail prices on drugs doesn't put the brakes on its explosive growth. The Chinese government seems to recognize that risk: On Tuesday it quietly ... [Published FiercePharma - Apr 17 2014]
First reported Apr 17 2014 - Updated Apr 17 2014 - 1 reports

England sets aside $31M to fund Sovaldi for sickest patients

Since before Sovaldi hit the market, Gilead ($GILD) has been justifying its high price with its unprecedented efficacy. While the next-gen hep C treatment costs $84,000 per 12-week course of treatment, it boasts a 90% cure rate--and that's convinced the ... [Published FiercePharma - Apr 17 2014]
First reported Apr 17 2014 - Updated Apr 17 2014 - 1 reports

Gilead's Sovaldi, GSK's Anoro stand out in 2014's blockbuster crop, report says

Want to take a guess about which three new drugs are marked for greatness in 2014? One of them is obvious. Another, not so much. And the third isn't approved yet.Gilead Sciences' ($GILD) hepatitis C pill Sovaldi is at the top of Thomson Reuters' annual ... [Published FiercePharma - Apr 17 2014]
First reported Apr 17 2014 - Updated Apr 17 2014 - 1 reports

Pharma's top 10 M&A deals of 2013

All things being relative, 2013 was a pretty good year for M&A in pharma. There were 169 deals valued at $76 billion last year, according to the information ninjas who dice the numbers at EvaluatePharma . That was a 15% jump in the number of deals and ... [Published FiercePharma - Apr 17 2014]
First reported Apr 16 2014 - Updated Apr 17 2014 - 1 reports

Reckitt CFO: Spinoff of pharma unit a 'strong option'

British consumer products maker Reckitt Benckiser said during a first-quarter business review today that it's moving closer to carving out its struggling pharmaceutical unit and listing it as a separate public company. A strategic review of the unit that ... [Published FiercePharma - Apr 16 2014]
First reported Apr 16 2014 - Updated Apr 17 2014 - 1 reports

EMA warns Herceptin vials stolen in Italy spreading through EU

Vials of Roche's cancer med Herceptin that were stolen in Italy are now showing up in other places in Europe, leading the European Medicines Agency (EMA) to issue an alert and Herceptin maker Roche to recall all of the batches from which the stolen drugs ... [Published FiercePharma - Apr 16 2014]
First reported Apr 16 2014 - Updated Apr 16 2014 - 1 reports

Amgen's Bradway nets $13.65M in 2013, sans Onyx bonus

Amgen ($AMGN) CEO Robert Bradway may have orchestrated 2013's biggest M&A deal in pharma, nabbing Onyx Pharmaceuticals for $10.4 billion last summer, but that wasn't enough to net him the kind of deal-related bonus some of his peers enjoy. But it's not ... [Published FiercePharma - Apr 16 2014]
First reported Apr 16 2014 - Updated Apr 16 2014 - 1 reports

Sanofi beefs up social media channels with Spanish Twitter push

Sanofi ($SNY) is stepping up its social media game with a new project in Spain. The French drugmaker has added a new Twitter handle to its Iberian lineup, @Sanofifarmacia, designed to create a pool of reference information and help community pharmacies ... [Published FiercePharma - Apr 16 2014]

Quotes

..."[T]he vast majority" of these new meds "are predicted to make sales of less than $1 billion by 2019."
"This is a major step forward for patients with this debilitating, and often life-threatening, disease and is evidence of NHS England's commitment to widen access to cutting edge drugs, treatments and therapies where both clinically appropriate and cost effective" James Palmer, NHS England's clinical director of specialized services, said in a statement
...Still, the information firm said, "the average deal value reached $708m last year, the highest since pre-crash levels, while the average sales multiple paid climbed for the third year in a row."
...allegations regarding the activity of a small number of individuals in our operations in Jordan and Lebanon," the company said in statement. "We started investigating using internal and external teams as soon as we became aware of these claims. These investigations have not yet concluded."

More Content

All (202) | News (202) | Reports (0) | Blogs (0) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Eventus attracts $2.72M for breast cancer Dx te... [Published FiercePharma - Apr 18 2014]
Novartis near to wrapping up $1.7B sale of part... [Published FiercePharma - Apr 17 2014]
Gilead's Sovaldi, GSK's Anoro stand out in 2014... [Published FiercePharma - Apr 17 2014]
England sets aside $31M to fund Sovaldi for sic... [Published FiercePharma - Apr 17 2014]
Gardasil dose reduction could boost EU sales fo... [Published FiercePharma - Apr 17 2014]
Pharma's top 10 M&A deals of 2013 [Published FiercePharma - Apr 17 2014]
Under fire from local pharmas, China backs off ... [Published FiercePharma - Apr 17 2014]
GlaxoSmithKline steps up bribery probes, eyeing... [Published FiercePharma - Apr 17 2014]
Sanofi beefs up social media channels with Span... [Published FiercePharma - Apr 16 2014]
Amgen's Bradway nets $13.65M in 2013, sans Onyx... [Published FiercePharma - Apr 16 2014]
EMA warns Herceptin vials stolen in Italy sprea... [Published FiercePharma - Apr 16 2014]
GlaxoSmithKline's new diabetes med faces formid... [Published FiercePharma - Apr 16 2014]
Judge halts Massachusetts governor's ban on pow... [Published FiercePharma - Apr 16 2014]
Reckitt CFO: Spinoff of pharma unit a 'strong o... [Published FiercePharma - Apr 16 2014]
New report finds Bydureon safest of new class o... [Published FiercePharma - Apr 16 2014]
AdverseEvents' Special Report: Examining the Co... [Published FiercePharma - Apr 16 2014]
Pharma sales force took a hit in North America ... [Published FiercePharma - Apr 15 2014]
Novartis' gain is consumers' $900M loss from st... [Published FiercePharma - Apr 15 2014]
Boehringer Ingelheim revenue slide cushioned by... [Published FiercePharma - Apr 15 2014]
Generics makers ask SCOTUS to let them proceed ... [Published FiercePharma - Apr 15 2014]
New drugs are J&J's Q1 heroes, spurring pharma ... [Published FiercePharma - Apr 15 2014]
Novartis marks 235 admin jobs for deletion amid... [Published FiercePharma - Apr 15 2014]
Roche cancer drugs Perjeta and Kadcyla drive st... [Published FiercePharma - Apr 15 2014]
An acquisition helps carry ERBA Diagnostics to ... [Published FiercePharma - Apr 15 2014]
Lupin recalls more Suprax on purity problems, a... [Published FiercePharma - Apr 14 2014]
Novartis backs away from once-ambitious RNAi re... [Published FiercePharma - Apr 14 2014]
Big Pharma tries to short-circuit France's move... [Published FiercePharma - Apr 14 2014]
New attention disorder could equal a big new AD... [Published FiercePharma - Apr 14 2014]
Polish prosecutors hit GlaxoSmithKline with thi... [Published FiercePharma - Apr 14 2014]
U.S. lawmakers join Lilly's attacks on Canada's... [Published FiercePharma - Apr 14 2014]
1 2 3 4 5 6 7
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.